Citations

Clear

3042 citation(s) found for "Kumar, S".

A global action agenda for turning the tide on fatty liver disease
Lazarus, Jeffrey V. , Mark, Henry E. , Allen, Alina M. , Arab, Juan Pablo , Carrieri, Patrizia , Noureddin, Mazen , Alazawi, William , Alkhouri, Naim , Alqahtani, Saleh A. , Anstee, Quentin M. , Brennan, Paul , Burra, Patrizia , Castro‐Narro, Graciela , Cortez‐Pinto, Helena , Cusi, Kenneth , Dedes, Nikos, Duseja, Ajay , Gastaldelli, Amalia , Hagström, Hannes , Huang, Terry T.‐K. , Ivancovsky‐Wajcman, Dana , Kautz, Achim, Kopka, Christopher J. , Krag, Aleksander , Newsome, Philip N. , Rinella, Mary E. , Silva, Marcelo , Tsochatzis, Emmanuel , Valenti, Luca , Zelber‐Sagi, Shira , Schattenberg, Jörn M. , Younossi, Zobair M. , Collaborators, on behalf of the Healthy Livers, Healthy Lives, Adams, Leon A. , Wong, Robert J. , Satapathy, Sanjaya K. , Alves‐Bezerra, Michele , Khader, Yousef , Graupera, Isabel , Grønbæk, Henning , Yılmaz, Yusuf , Thiele, Maja , Lazo, Mariana , Hickman, Ingrid J. , Idılman, Ramazan , Kim, Seung Up , Desalegn, Hailemichael , Oliveira, Cláudia P. , Crespo, Javier , Velasco, J.A. Velarde-Ruiz , Goossens, Nicolas , George, Jacob , George, Jacob , Caussy, Cyrielle , Alswat, Khalid , Bataller, Ramon A , Berg, Thomas , Brennan, Paul N , Castro-Narro, Graciela E , Cortez-Pinto, Helena , Duseja, Ajay , Francque, Sven M , Gastaldelli, Amalia , Hagström, Hannes , Huang, Terry T K , Ivancovsky Wajcman, Dana , Kopka, Christopher J , Krag, Aleksander , Newsome, Philip N , Romero, Diana , Sarin, Shiv Kumar , Terrault, Norah , Tsochatzis, Emmanuel A , Valenti, Luca , Schattenberg, Jörn M , Wong, Vincent Wai-Sun , Sathapathy, Sanjaya , Arab, Juan P , Lazarus, Jeffrey V , Wong, Robert J , Allen, Alina M , Anstee, Quentin M , Hickman, Ingrid J , Rinella, Mary , Yilmaz, Yusuf , Thiele, Maja , Lazo, Mariana , Crespo, Javier , Carrieri, Patrizia , Idilman, Ramazan , Goossens, Nicolas , Velarde-Ruiz Velasco, José Antonio , Desalgn, Hailemicheal , George, Jacob , Arrese, Marco , Francque, Sven , Spearman, C Wendy , Terrault, Norah A. , Villota‐Rivas, Marcela , Wong, Vincent Wai‐Sun , Collaborators, on behalf of the Healthy Livers, Healthy Lives

Mayo Clinic

Hepatology | August 4, 2023 | Volume: 79 | Issue: 2 | Pages: 502-523

10.1097/hep.0000000000000545 | PMID 37540183 Get It

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial
Richardson, Paul G. , Venner, Christopher P. , Bahlis, Nizar J. , Offner, Fritz , White, Darrell , Karlin, Lionel, Benboubker, Lotfi , Voog, Éric , Suzuki, Kenshi , Zhang, Xiaoquan , Twumasi‐Ankrah, Philip, Labotka, Richard, Rifkin, Robert M. , Kumar, Shaji , Bahlis, Nizar Jacques , Suzuki, Kenshi , Richardson, Paul Gerard Guy , Facon, Thierry T.F. , Karlin, Lionel , Yoon, Sung‐Soo , Shibayama, Hirohiko , Villarreal, Miguel, Lonial, Sagar , Rajkumar, S. Vincent , Moreau, Philippe

Mayo Clinic

eJHaem | August 3, 2023 | Volume: 4 | Issue: 4 | Pages: 995-1005

10.1002/jha2.759 | PMID 38024593 Get It

AbstractDeeper responses are associated with longer survival in multiple myeloma (MM); however, limited data exist on the impact of response kinetics on outcomes. We investigated progression‐free survival (PFS) and duration of response (DOR) by response depth and in early (best confirmed response 0–4 months; n = 424) versus late responders (best confirmed response >4 months; n = 281). Newly diagnosed patients enrolled in TOURMALINE‐MM2 receiving ixazomib‐lenalidomide‐dexamethasone (IRd) (n = 351) or placebo‐Rd (n = 354) were evaluated post hoc. Deeper responses were associated with longer PFS (complete response [CR] not reached [NR], very good partial response [VGPR] 37.2 months, partial response [PR] 16.4 months) and DOR (CR NR, VGPR 42.6 months, PR 15.4 months). Among patients with a PFS (n = 511) or DOR (n = 484) of ≥6 months who achieved ≥PR, median PFS was prolonged among late versus early responders receiving IRd (59.7 vs. 17.9 months) or placebo‐Rd (56.6 vs. 12.4 months), as was median DOR (IRd, NR vs. 20.9 months; placebo‐Rd, 58.2 vs. 11.7 months). While the treatment paradigm for newly diagnosed MM is treatment to progression, our findings suggest slowness of response to a proteasome inhibitor‐immunomodulatory drug‐steroid combination is not a negative predictor of outcome.
Recent Advances in Temporomandibular Joint Surgery
Wroclawski, Catherine, Mediratta, Jai Kumar , Fillmore, W. Jonathan

Mayo Clinic

Medicina | August 2, 2023 | Volume: 59 | Issue: 8 | Pages: 1409

10.3390/medicina59081409 | PMID 37629699 Get It

Temporomandibular disorders (TMDs) affect a high percentage of children and adults worldwide. Surgery may be indicated in severe or recalcitrant cases. Several recent advancements in TMD and temporomandibular joint (TMJ) surgery have elevated understanding and the ability to treat affected patients. We discuss recent advances in TMD epidemiology, juvenile idiopathic arthritis (JIA) of the TMJ, and surgical techniques and technologies. Technical advancements have been identified in TMJ arthroscopy, the treatment of TMJ subluxation and dislocation, and extended prosthetic total TMJ reconstruction (eTMJR). Overall, this review provides valuable insights into significant recent advancements in TMJ disorders and their surgical management.
GeneAI 3.0: Powerful, Novel, Generalized Hybrid and Ensemble Deep Learning Frameworks for miRNA Classification of species-specific Stationary Patterns from Nucleotides
Laird, John R. , Singh, Inder M. , Mantella, Laura E. , Saba, Luca , Suri, Jasjit S. , Singh, Jaskaran , Khanna, Narendra N. , Rout, Ranjeet Kumar , Singh, Narpinder , Kalra, Mannudeep K. , Johri, Amer M. , Isenović, Esma R. , Fouda, Mostafa M. , Fatemi, Mostafa , Suri, Jasjit S.

Mayo Clinic

No container title available | July 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3161256/v1 Get It

Abstract Background and Motivation: Due to the intricate relationship between the small non-coding ribonucleic acid (miRNA) sequences, the classification of miRNA species, namely Human, Gorilla, Rat, and Mouse is challenging. Previous methods are not robust and accurate. In this study, we present GeneAI 3.0 (AtheroPoint™, Roseville, CA, USA), a powerful, novel, and generalized method for extracting features from the fixed patterns of purines and pyrimidines in each miRNA sequence in ensemble paradigms in machine learning (EML) and convolutional neural network (CNN)-based deep learning (EDL) frameworks. Method: GeneAI 3.0 utilized five conventional (Entropy, Dissimilarity, Energy, Homogeneity, and Contrast), and three contemporary (Shannon entropy, Hurst exponent, Fractal dimension) features, to generate a compositefeature set from given miRNA sequences which were then passed into our ML and DL classification framework. A set of 11 new classifiers was designed consisting of five EML and six EDL for binary/multiclass classification. It was benchmarked against 9 solo ML (SML), 6 solo DL (SDL), 12 hybrid DL (HDL) models, resulting in a total of 11+27=38 models were designed. Four hypotheses were formulated and validated using explainable AI (XAI) as well as reliability/statistical tests. Results: The order of the mean performance using accuracy (ACC)/area-under-the-curve (AUC) of the 24 DL classifiers was: EDL>HDL>SDL. The mean performance of EDL models with CNN layers was superior to that without CNN layers by 0.73%/0.92%. Mean performance of EML models was superior to SML models with improvements of ACC/AUC by 6.24%/6.46%. EDL models performed significantly better than EML models, with a mean increase in ACC/AUC of 7.09%/6.96%. The GeneAI 3.0 tool produced expected XAI feature plots, and the statistical tests showed significant p-values. Conclusions: Ensemble models with composite features are highly effective and generalized models for effectively classifying miRNA sequences.
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
Yadav, Udit , Kumar, Shaji , Greipp, Patricia T. , Buadi, Francis K. , Dingli, David , Lacy, Martha Q. , Bergsagel, P. Leif , Sher, Taimur , Hayman, Suzanne R. , Kapoor, Prashant , Binder, Moritz , Warsame, Rahma , Kourelis, Taxiarchis , Breen, William G. , Kyle, Robert A. , Bergsagel, P. Leif , Kumar, Shaji K , Dispenzieri, Angela , Greipp, Patricia T , Buadi, Francis K , Lacy, Martha Q , Roy, Vivek , Parrondo, Ricardo D , Leung, Nelson , Cook, Joselle M , Binder, Moritz , Muchtar, E , Warsame, Rahma , Kourelis, Taxiarchis , Seth, Abhishek, Lester, Scott C. , Dingli, David , Baughn, Linda B. , Dispenzieri, Angela , Ketterling, Rhett P. , Jevremović, Dragan , Fonseca, Rafaël , Ailawadhi, Sikander , Roy, Vivek , Leung, Nelson , Cook, Joselle , Muchtar, Eli , Go, Ronald S. , Lin, Yi , Seth, Abhishek, Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson I.

Mayo Clinic

Blood | July 26, 2023 | Volume: 142 | Issue: 22 | Pages: 1871-1878

10.1182/blood.2023021187 | PMID 37494698 Get It

Abstract Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic abnormalities by fluorescence in situ hybridization (FISH) in the clonal plasma cells, obtained either directly from the diagnostic SBP tissue or the corresponding bone marrow examination at the time of diagnosis, is associated with a shorter time to progression (TTP) to MM is unknown. This study evaluated all patients diagnosed with SBP at the Mayo Clinic from January 2012 to July 2022. The presence of del(17p), t(14;16), t(4;14), or +1q (gain or amplification) by FISH in clonal plasma cells was defined as HR. A total of 114 patients were included in this cohort, and baseline FISH was available for 55 patients (48%), of which 22 were classified as HR (40%). The median TTP to MM for patients with SBP and HR FISH was 8 months (95% confidence interval [CI], 6.3-26) compared with 42 months (95% CI, 25-not reached [NR]) in patients with SBP without HR FISH (P < .001). In a multivariate analysis, only HR FISH was a significant predictor for shorter TTP to MM, independent of minimal marrow involvement and an abnormal serum free light chain ratio at diagnosis. Deletion (17p) and gain 1q abnormalities were the most common FISH abnormalities responsible for the short TTP to MM. Thus, assessing for HR FISH abnormalities in clonal plasma cells derived from either the diagnostic SBP tissue or the staging bone marrow examination of patients with newly diagnosed SBP is feasible and prognostic for a shorter TTP to MM.
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Parodis, Ioannis , Sen, Parikshit , Ravichandran, Naveen , Day, Jessica , Joshi, Mrudula , Jagtap, Kshitij , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Colunga-Pedraza, I. J. , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Gupta, Vikas , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danieli, Maria Giovanna , Giollo, Alessandro, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos, Aharonov, Or, bouchti, Imane El, Baba, Zineb, Maurier, François, Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Giollo, Alessandro , Gupta, Latika , Agarwal, Vishwesh , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Gutiérrez, Carlos Enrique Toro , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Saavedra, Miguel A , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Joshi, Mrudula , Day, Jessica , Parodis, Ioannis , Nune, Arvind , Naveen, R , Agarwal, Vikas , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , Sen, Parikshit , Andreoli, Laura , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Agarwal, Vishwesh , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Makol, Ashima , Barman, Bhupen , Torre, Ignacio García‐De La , Goo, Phonpen Akawatcharangura , Chen, Yi‐Ming , Halabi, Hussein , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Pilania, Rakesh Kumar , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Alunno, Alessia , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira, Kimura, Naoki, Gono, Takahisa , Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Giannini, Margherita , Maurier, F. , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , So, Ho , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | July 25, 2023 | Volume: 63 | Issue: 5 | Pages: 1341-1351

10.1093/rheumatology/kead382 | PMID 37505460 Get It

Abstract Objectives We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares and AID-related treatment modifications were analysed upon diagnosis of AID vs healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine. Results Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, P = 0.01; minor AE 40% vs 25.9%, P = 0.03; major AE 17.5% vs 4.6%, P < 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination disease flares were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a disease flare were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively. Conclusion This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and for the fetus by passive immunization appear to outweigh potential risks.
Extranodal Natural Killer/T-cell Lymphoma, Nasal Type, Misdiagnosed as Fungal Sinusitis
Agarwal, Amit , Bathla, Girish , Bathla, Girish , Agarwal, Amit Kumar , Gupta, Vivek

Mayo Clinic

Radiology: Imaging Cancer | July 21, 2023 | Volume: 5 | Issue: 4 | Pages: No page available

10.1148/rycan.230054 | PMID 37477564 Get It

Global prospective case series of ERCPs using a single-use duodenoscope
Bruno, Marco J. , Beyna, Torsten , Carr‐Locke, David L. , Chahal, Prabhleen , Costamagna, Guido , Devereaux, Benedict , Giovannini, Marc, Khor, Christopher , Lau, James Y., May, Gary R. , Muthusamy, V. Raman , Petersen, Bret T. , Raijman, Isaac , Reddy, D. Nageshwar , Ross, Andrew S., Sejpal, Divyesh V., Sherman, Stuart , Siddiqui, Uzma D. , Ziady, Christopher, Peetermans, Joyce , Rousseau, Matthew , Slivka, Adam, Group, EXALT Single-use Duodenoscope Study, Fichera, Alessandro , Pleskow, Douglas , Goenka, Mahesh Kumar , Patel, Sandeep , Petersen, Bret T. , Pleskow, Douglas K. , Repici, Alessandro , Group, EXALT Single-use Duodenoscope Study

Mayo Clinic

Endoscopy | July 18, 2023 | Volume: 55 | Issue: 12 | Pages: 1103-1114

10.1055/a-2131-7180 | PMID 37463599 Get It

Background The first commercialized single-use duodenoscope was cleared by the US Food and Drug Administration in December 2019. Data regarding endoscopic retrograde cholangiopancreatography (ERCP) using a single-use duodenoscope are needed on a broader range of cases conducted by endoscopists with varying levels of experience in a wide range of geographic areas. Methods 61 endoscopists at 22 academic centers in 11 countries performed ERCP procedures in adult patients aged ≥ 18. Outcomes included ERCP completion for the intended indication, rate of crossover to a reusable endoscope, device performance ratings, and serious adverse events (SAEs). Results Among 551 patients, 236 (42.8 %) were aged > 65, 281 (51.0 %) were men, and 256 (46.5 %) had their procedure as an inpatient. ERCPs included 196 (35.6 %) with American Society for Gastrointestinal Endoscopy complexity of grades 3–4. A total of 529 ERCPs (96.0 %) were completed: 503 (91.3 %) using only the single-use duodenoscope, and 26 (4.7 %) with crossover to a reusable endoscope. There were 22 ERCPs (4.0 %) that were not completed, of which 11 (2.0 %) included a crossover and 11 (2.0 %) were aborted cases (no crossover). Median ERCP completion time was 24.0 minutes. Median overall satisfaction with the single-use duodenoscope was 8.0 (scale of 1 to 10 [best]). SAEs were reported in 43 patients (7.8 %), including 17 (3.1 %) who developed post-ERCP pancreatitis. Conclusions In academic medical centers over a wide geographic distribution, endoscopists with varying levels of experience using the first marketed single-use duodenoscope had good ERCP procedural success and reported high performance ratings for this device.
Pediatric Aerodigestive Medicine: Advancing Collaborative Care for Children With Oropharyngeal Dysphagia
Krasaelap, Amornluck , Sabe, Ramy , Bhardwaj, Vrinda, Lerner, Diana G. , Gold, Benjamin D., Boesch, R. Paul , Allmen, Daniel von, Williams, Dana , Chiou, Eric , DeBoer, Emily M. , Hysinger, Erik B. , Maybee, Jennifer , Khlevner, Julie , Larson, Kara , Morris, Kimberly , Jalali, Lauren , McSweeney, Maireade E. , Greifer, Melanie , Rutter, Michael J. , Williams, Nina, Subramanyan, Ram Kumar, Ryan, Matthew J. , Acra, Sari , Pentiuk, Scott, Friedlander, Joel A. , Sobol, Steven E., Kaul, Ajay , Dorfman, Lev , Darbari, Anil , Prager, Jeremy D. , Rosen, Rachel , Cocjin, Jose, Kumar, S. Ram , Boesch, Richard Paul, Kumar, S Ram , Rosen, Rachel , Duncan, Daniel R. , Faure, Christophe C. , Brigger, Matthew T. , Mousa, Hayat M.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | July 13, 2023 | Volume: 77 | Issue: 4 | Pages: 460-467

10.1097/mpg.0000000000003882 | PMID 37438891 Get It

Objectives:Aerodigestive disorders encompass various pathological conditions affecting the lungs, upper airway, and gastrointestinal tract in children. While advanced care has primarily occurred in specialty centers, many children first present to general pediatric gastroenterologists with aerodigestive symptoms necessitating awareness of these conditions. At the 2021 Annual North American Society for Pediatric Gastroenterology, Hepatology and Nutrition meeting, the aerodigestive Special Interest Group held a full‐day symposium entitled, Pediatric Aerodigestive Medicine: Advancing Collaborative Care of Children with Aerodigestive Disorders. The symposium aimed to underline the significance of a multidisciplinary approach to achieve better outcomes for these complex patients.Methods:The symposium brought together leading experts to highlight the growing aerodigestive field, promote new scientific and therapeutic strategies, share the structure and benefits of a multidisciplinary approach in diagnosing common and rare aerodigestive disorders, and foster multidisciplinary discussion of complex cases while highlighting the range of therapeutic and diagnostic options. In this article, we showcase the diagnostic and therapeutic approach to oropharyngeal dysphagia (OPD), one of the most common aerodigestive conditions, emphasizing the role of a collaborative model.Conclusions:The aerodigestive field has made significant progress and continues to grow due to a unique multidisciplinary, collaborative model of care for these conditions. Despite diagnostic and therapeutic challenges, the multidisciplinary approach has enabled and greatly improved efficient, high‐quality, and evidence‐based care for patients, including those with OPD.
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma
Zanwar, Saurabh , Kapoor, Prashant , Binder, Moritz , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hwa, Yi L. , Hobbs, Miriam, Kourelis, Taxiarchis , Lacy, Martha Q. , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Ho, Matthew , Binder, Moritz , Dispenzieri, Angela , Gonsalves, Wilson , Hwa, Yi, Kourelis, Taxiarchis , Leung, Nelson , Muchtar, E , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Dingli, David , Ho, Matthew , Lin, Yi , Buadi, Francis K. , Dispenzieri, Angela , Gertz, Morie A. , Gonsalves, Wilson I. , Leung, Nelson , Muchtar, Eli , Jevremović, Dragan , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | July 8, 2023 | Volume: 98 | Issue: 10 | Pages: 1540-1549

10.1002/ajh.27023 | PMID 37421603 Get It

Abstract Extramedullary multiple myeloma (EMM) can present either at initial diagnosis (de novo) or at disease relapse (secondary) and confers an aggressive clinical course. Limited data exist for choosing the optimal therapy for EMM and this remains an area of unmet clinical need. After excluding paraskeletal multiple myeloma and primary plasma cell leukemia, we identified 204 (68%) patients with secondary EMM and 95 (32%) with de novo EMM between January 01, 2000 and 31 December, 2021. The median overall survival (OS) was 0.7 (95% CI: 0.6–0.9) years for secondary EMM and 3.6 (95%CI: 2.4–5.6) years for de novo EMM. The median progression‐free survival (PFS) with initial therapy was 2.9 months (95% CI: 2.4–3.2 months) for secondary EMM and 12.9 months (95% CI: 6.7–18 months) for de novo EMM. Patients with secondary EMM treated with CAR‐T therapy ( n = 20) achieved a partial response (PR) or better in 75% with a median PFS of 4.9 months (3.1 months‐not reached; NR). Patients with EMM treated with bispecific antibodies ( n = 12) achieved a ≥ PR in 33%, with a median PFS of 2.9 months (95%CI: 2.2 months‐NR). In a matched cohort, multivariate logistic regression analysis demonstrated younger age at diagnosis, 1q duplication, and t (4;14) at diagnosis of MM to be independent predictors of development of secondary EMM. Presence of EMM was independently associated with inferior OS in the matched cohorts for both de novo (HR 2.9 [95% CI: 1.6–5.4], p = .0007) and secondary EMM (HR 1.5 [95% CI: 1.1–2], p = .001).